HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS CASE PRESENTATION

Authors

Lenore Bonanno PA, MS, DMSc-Fellow, University of Lynchburg, Virginia; Stony Brook University Hospital, New York; United Medical HousecallsFollow
Bonnie Kiner-Strachan MD, Stony Brook University Hospital, New YorkFollow
Ann-Leslie Zaslav PhD, Stony Brook University Hospital, New YorkFollow
Kristen Delaney PA-C, United Medical Housecalls, New YorkFollow
Claudio Ginebra RPA-C, Preferred Professional Medical of Ronkonkoma, New YorkFollow

Specialty

Hematology/Oncology

Advisor

Dr. Thomas Colletti, DHSc, PA-C, DFAAPA

Abstract

Purpose: The purpose of this article is to discuss a case presentation of a rare form of acquired Hemophagocytic Lymphohistiocytosis (HLH) and review the standard of care in addition to current therapeutic options for the disease.

Method: A PubMed literature search conducted with search terms hemophagocytic lymphohistiocytosis, guidelines, survival, treatment, and EBV, allowed for the review and reference to nine applicable sources for this case presentation.

Results: Increased observation of young adults with relapsed or refractory secondary HLH is needed to evaluate for remission with a new monoclonal antibody (mAb) therapy versus standard of care chemotherapeutic protocols with stem cell transplant.

Conclusion: The patient is currently under active surveillance for relapse and possible treatment with emapalumab for secondary HLH to determine if remission-cure can be achieved. Emapalumab is a monoclonal antibody recently approved to treat relapsed and refractory sHLH.

Recommended Citation

Bonanno L, Kiner-Strachan B, Zaslav A, Delaney K, Ginebra C. HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS CASE PRESENTATION. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2019; 1(4).